Quick Answer
BioCorRx Inc. reported Total Revenue of $797.2 thousand for fiscal year 2025.
BioCorRx Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $797.2K +10301.1% |
$7.7K -91.4% |
$89.2K -58.3% |
$213.8K +343.0% |
$48.3K -60.6% |
$122.6K -49.0% |
| Net Income | -$3.44M +32.6% |
-$5.11M -35.4% |
-$3.77M +13.9% |
-$4.38M +16.0% |
-$5.21M -48.6% |
-$3.51M +42.0% |
| Diluted EPS | -$0.19 +61.2% |
-$0.49 | — | — | — | — |
| Total Assets | $2.15M +456.4% |
$385.9K -0.8% |
$388.9K -49.3% |
$766.6K -6.5% |
$820.0K -55.1% |
$1.83M -53.5% |
| Cash and Equivalents | — | — | — | — | — | $592.1K -77.6% |
| Long-Term Debt | — | — | — | $0.00 -100.0% |
$99.9K | — |
| Stockholders Equity | -$11.22M +7.4% |
-$12.12M -23.4% |
-$9.82M -21.6% |
-$8.08M -16.0% |
-$6.96M -65.3% |
-$4.21M -297.6% |
| R&D Expense | $1.77M +19.3% |
$1.48M +66.4% |
$891.1K -38.9% |
$1.46M -9.1% |
$1.61M -62.4% |
$4.27M +279.9% |
| Operating Income | -$4.83M +5.7% |
-$5.12M -35.2% |
-$3.79M +19.4% |
-$4.70M +14.7% |
-$5.51M +26.5% |
-$7.49M -34.7% |
| Gross Profit | — | — | — | — | — | — |
| Shares Outstanding | 24.49M +84.1% |
13.30M +53.3% |
8.67M +12.4% |
7.72M +15.2% |
6.70M +22.6% |
5.46M +2.6% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $635.2K | — | +256.4% |
| Net Income | September 30, 2025 | -$1.92M | -28.9% | -55.5% |
| Diluted EPS | September 30, 2025 | -$0.11 | +21.4% | -57.1% |
| Total Assets | September 30, 2025 | $7.53M | +1070.6% | +12.8% |
| Cash and Equivalents | June 30, 2022 | $111.5K | -84.1% | -47.7% |
| Stockholders Equity | September 30, 2025 | -$13.48M | -14.0% | -6.8% |
| R&D Expense | September 30, 2025 | $1.00M | +118.3% | +238.4% |
| Operating Income | September 30, 2025 | -$1.95M | -17.2% | -37.6% |
| Gross Profit | September 30, 2014 | $349.7K | +26.0% | +83.3% |
| Shares Outstanding | September 30, 2025 | 11.21M | +0.0% | -35.1% |
- BioCorRx Inc. reported Total Revenue of $797.2 thousand for fiscal year 2025.
- BioCorRx Inc. showed an increase of +10301.1% in Total Revenue compared to the prior fiscal year.
- BioCorRx Inc. reported Net Income of -$3.44 million for fiscal year 2025.
- BioCorRx Inc. showed an increase of +32.6% in Net Income compared to the prior fiscal year.
- BioCorRx Inc. reported Diluted EPS of $0.19 per share (loss) for fiscal year 2025.
- BioCorRx Inc. showed an increase of +61.2% in Diluted EPS compared to the prior fiscal year.
- BioCorRx Inc. reported Total Assets of $2.15 million for fiscal year 2025.
- BioCorRx Inc. showed an increase of +456.4% in Total Assets compared to the prior fiscal year.
- BioCorRx Inc. reported Cash and Equivalents of $592.1 thousand for fiscal year 2020.
- BioCorRx Inc. showed a decrease of -77.6% in Cash and Equivalents compared to the prior fiscal year.
- BioCorRx Inc. reported Long-Term Debt of $0.00 for fiscal year 2022.
- BioCorRx Inc. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- BioCorRx Inc. reported Stockholders Equity of -$11.22 million for fiscal year 2025.
- BioCorRx Inc. showed an increase of +7.4% in Stockholders Equity compared to the prior fiscal year.
- BioCorRx Inc. reported R&D Expense of $1.77 million for fiscal year 2025.
- BioCorRx Inc. showed an increase of +19.3% in R&D Expense compared to the prior fiscal year.
- BioCorRx Inc. reported Operating Income of -$4.83 million for fiscal year 2025.
- BioCorRx Inc. showed an increase of +5.7% in Operating Income compared to the prior fiscal year.
- BioCorRx Inc. reported Gross Profit of $554.8 thousand for fiscal year 2013.
- BioCorRx Inc. showed an increase of +19.1% in Gross Profit compared to the prior fiscal year.
- BioCorRx Inc. reported Shares Outstanding of 24.49 million shares for fiscal year 2025.
- BioCorRx Inc. showed an increase of +84.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: